Compare Petróleo Brasileiro SA (PBR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs ResMed Inc. — how do they compare? Petróleo Brasileiro SA trades at $25.3 (market cap $151.94B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Petróleo Brasileiro SA is far larger — about 4.8× ResMed Inc.'s market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and ResMed Inc. for 51 Days on average.
| PBR | RMD | |
|---|---|---|
Market Cap | $151.94B | $31.89B |
Volume | 30,240,092 | 618,314 |
Sector | Energy | Health |
52-Week High | $25.30 | $275.96 |
52-Week Low | $11.54 | $182.82 |
Typical Hold Time | 25 Days | 51 Days |
Enterprise Value | $212.36B | $31.24B |
Dividend Yield | 6.79% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $24.69, up 2.92% today, with a bullish technical signal from moving averages despite overbought RSI readings. The stock shows strong fundamentals with a low P/E of 6.24 and robust profitability, including a 24.52% net income margin. Recent news highlights growth via new oil discoveries and LNG deals, though Q1 2026 earnings missed expectations.
Outlook remains positive given low valuation, high profitability, and strategic expansions, but risks include political interference in Brazil, volatile oil prices, and execution challenges in new projects. Analyst consensus is Buy with a $22.33 target, slightly below current price, suggesting cautious optimism near-term.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
